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Abstract
Background: Cerebrospinal fluid (CSF) biomarkers reflect ongoing processes in the brain. Growth-associated
protein 43 (GAP-43) is highly upregulated in brain tissue shortly after experimental ischemia suggesting the CSF
GAP-43 concentration may be altered in ischemic brain disorders. CSF GAP-43 concentration is elevated in
Alzheimer’s disease patients; however, patients suffering from stroke have not been studied previously.
Methods: The concentration of GAP-43 was measured in longitudinal CSF samples from 28 stroke patients
prospectively collected on days 0–1, 2–4, 7–9, 3 weeks, and 3–5 months after ischemia and cross-sectionally in 19
controls. The stroke patients were clinically evaluated using a stroke severity score system. The extent of the brain
lesion, including injury size and degrees of white matter lesions and atrophy were evaluated by CT and magnetic
resonance imaging.
Results: Increased GAP-43 concentration was detected from day 7–9 to 3 weeks after stroke, compared to day 1–4
and to levels in the control group (P = 0.02 and P = 0.007). At 3–5 months after stroke GAP-43 returned to admission
levels. The initial increase in GAP-43 during the nine first days was associated to stroke severity, the degree of white
matter lesions and atrophy and correlated positively with infarct size (rs = 0.65, P = 0.001).
Conclusions: The transient increase of CSF GAP-43 is important to take into account when used as a biomarker for
other neurodegenerative diseases such as Alzheimer’s disease. Furthermore, GAP-43 may be a marker of neuronal
responses after stroke and additional studies confirming the potential of CSF GAP-43 to reflect severity and
outcome of stroke in larger cohorts are warranted.
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Background
The presynaptic protein Growth associated protein 43
(GAP-43) is highly expressed during neuronal develop-
ment and synaptogenesis and thereafter sustained in
presynaptic terminals in the hippocampus and associate
cortex in the adult human brain [1–3]. GAP-43 is in-
volved in the regulation of axonal outgrowth, synaptic
plasticity, and learning and memory functions [4–9].
Considering the function of GAP-43, it may also be in-
duced by neuronal damage caused by stroke, traumatic
brain injury and epilepsy [8, 10–14]. Highly elevated
levels of GAP-43 protein in the peri-infarct region after
experimentally induced cerebral ischemia have been well
documented in rodents [11, 14–17]. Additionally, in ro-
dent stroke models, a rapid induction of both GAP-43
gene and protein expression in the brain is reportedly
present already at day one after ischemia and sustained
up to 28 days and GAP-43 was suggested to be an early
and sensitive marker of neuronal damage after ischemia
[11, 17, 18]. However, GAP-43 quantification has to our
knowledge not been measured in any body fluids of stroke
patients. Novel stroke biomarkers could improve clinical
diagnosis, predict prognosis, and guide therapeutic inter-
ventions. Furthermore, even though CSF GAP-43 concen-
tration could become useful as a biomarker of neuronal
injury after stroke, it is equally important to examine con-
founding conditions that may affect the use of CSF
GAP-43 as a biomarker or outcome measurement in other
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neuronal diseases. We evaluated CSF GAP-43 concentra-
tion in longitudinally sampled stroke patients to 1) further
determine the pathogenic mechanisms of increased CSF
GAP-43 concentration, and 2) investigate the biomarker
potential of CSF GAP-43 after stroke.
Methods
Study participants and sample collection
The study was approved by the ethics committee for medical
research at the University of Gothenburg, Sweden. Longitu-
dinal CSF samples were collected prospectively from 28 pa-
tients with an acute ischemic stroke that occurred within the
first 3 days of admission at Sahlgrenska University Hospital,
Department of Neurology, between September 1992 and
January 1994. Exclusion criteria were patients with a history
of previous stroke, malignant or autoimmune diseases, se-
vere infections, or taking immunosuppressive drugs. When
possible, CSF samples were collected on up to five occasions;
at admission to the emergency ward at day 0–1, and then
day 2–4, day 7–9, 3 weeks and 3–5months. CSF samples
were taken by lumbar puncture in the L3/L4 or L4/L5 inter-
space, the first 12ml of CSF was collected in polypropylene
tubes, centrifuged at 2000 g for 10min, and stored at 80 °C
pending biochemical analyses.
All stroke patients were clinically evaluated in a standard-
ized way, as described previously [19]. Briefly, stroke severity
was evaluated using a modified Scandinavian Stroke Scale
Index (SSI) [19, 20]. The modified SSI is built on clinical scor-
ing of seven parameters (between 1 and 5): consciousness,
speech, facial paralysis, gait and physical strength in hand, arm
and leg. In the modified version the maximum score is 27 and
a higher score indicates increased severity of symptoms. Brain
atrophy and infarct size was evaluated by magnetic resonance
imaging (MRI) and computed tomography (CT) as previously
described [19]. Atrophy in patients was scored as nor-
mal (n = 9), mild (n = 8), moderate (n = 4), and pro-
nounced (n = 3), while white matter lesion status was
scored as normal (n = 15), general-light (n = 1),
general-moderate (n = 3), and cortical-light (n = 5) on
T2-weighted MRI scans. Two patients lacked infor-
mation about atrophy and white matter lesion, and
two additional patients did not have enough samples
for longitudinal analysis. Therefore, there were 24
patients for analysis of associations between these
clinical measures and GAP-43 concentration. The
control group consisted of healthy volunteers, with-
out history, symptoms or signs of cognitive distur-
bances, neurological or psychiatric symptoms.
Cerebrospinal fluid growth associated protein 43 enzyme-
linked immunosorbent assay
CSF GAP-43 concentration was measured by an in house
enzyme-linked immunosorbent assay (ELISA) described in
detail previously [21], with minor modifications. Microwell
modules (Thermo Fisher Scientific, Massachusetts, USA)
were coated with a mouse anti-GAP-43 antibody (1.35 μg/
ml NM4, Fujirebio, Ghent, Belgium) in carbonate buffer
pH 9.6, overnight at 4 °C. After washing in 0.05%Tween/
phosphate buffered saline (PBST), wells were blocked with
2% non-fat milk/PBST (assay diluent) for 1 h at room
temperature, frozen at − 20 °C until further use. After add-
itional washes, in-house recombinant full length GAP-43
calibrators (78 pg/ml - 5000 pg/ml), blanks, control samples
and CSF samples pre-diluted 1:2 in assay diluent were
co-incubated with a rabbit detector antibody (0.20 μg/ml
ABB-135, Nordic Biosite, Täby, Sweden) overnight at 4 °C.
Then, plates were washed and incubated with anti-rabbit HRP
(1:20000, IgG (H+L, Cross-adsorbed Secondary Antibody
horse radish peroxidase, ThermoFisherScientific, USA) for 2 h
in 1% bovine serum albumin/PBST. After subsequent washes,
wells were incubated for 30min with 3,3′,5,5′-tetramethylben-
zidine (KemEnTech Diagnostics) in dark. The color reaction
was stopped by addition of 0.2M H2SO4 and the absorbance
was read in a Sunrise microplate absorbance reader (Tecan
group, Männedorf, Switzerland) at 450 nm (650 nm as refer-
ence value). Cerebrospinal fluid sample concentration was cal-
culated via interpolation from the calibrator curve (4PL
weighted 1/Y2).
Assay validation
For CSF GAP-43 assay characterization, intra- and
inter-assay precision, measurement range, recovery, parallel-
ism, selectivity and sample storage stability was evaluated.
For intra- and inter-assay precision, five duplicates of two
samples with high and low concentrations, respectively, were
analyzed on 5 different days. Two technicians were involved
in the acquisition of data. For determination of measurement
range (lower limit of quantification (LLOQ) and upper limit
of quantification (ULOQ)), calibration curve data from 5
runs were used. The relative error of the back-calculated
concentrations for the calibrators was plotted as a function
of concentration, and LLOQ and ULOQ determined as cali-
brator points with < 20% relative errors. Parallelism was de-
termined in duplicates of one sample analyzed as neat and
diluted × 2, × 4, × 8, × 16 and × 32 times in assay diluent. Re-
covery was determined in two samples spiked with the
GAP-43 calibrator. Neurogranin interference was deter-
mined in duplicates of one neat sample and the same with
10 ng/ml recombinant neurogranin protein spike was
measured. Protein stability was evaluated by dividing 3
samples into nine aliquots where one was directly placed
at − 80 °C, and the others stored at − 20 °C or at 4 °C over-
night or for 1 week, at room temperature for 24 h, or
freeze-thawed 1–4 times.
Statistical analysis
Because the longitudinal trajectory of GAP-43 values ap-
peared to be nonlinear, the data was initially analyzed in
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two parts. First, a linear mixed effects model was fit on
measurements taken between before 9 days to test the
hypothesis that GAP-43 increases directly after stroke.
The model included random intercepts and slopes, and time
was discretized into Days 0–1, Days 2–3, and Days 7–9. Age
and sex were included as covariates and GAP-43 concentra-
tions were normalized for each individual relative to their
baseline measurement. Next, the same form of mixed model
was fit on measurements taken from Days 7–9, 2–4weeks,
and 3–5months in order to test the hypothesis that GAP-43
returns to normal levels over time. Differences in GAP-43
concentration across groups were analyzed using approximate
t tests on the estimated marginal means. The Pearson correl-
ation coefficient was calculated between subject-specific slopes
for the first model of early measurements and the subject-spe-
cific slopes of the second model of late measurements to
understand the relationship between initial change and late
change in GAP-43 concentrations.
A linear mixed model was then fit on longitudinal stroke se-
verity information, again with random intercepts and slopes.
The relationship between GAP-43 change and stroke severity
change was subsequently assessed by calculating the Pearson
correlation coefficient between the subject-specific slopes of
stroke severity and subject-specific slopes of GAP-43 as esti-
mated from the respective mixed effects models. The associ-
ation between GAP-43 change and infarct size was also
computed using the Pearson correlation coefficient.
Additionally, group differences in GAP-43 change across
discrete levels of white matter lesions and across discrete
levels of brain atrophy were analyzed by fitting the same lin-
ear mixed effects model as above but with white matter le-
sion (or brain atrophy) status included as an interaction with
time. Overall group difference was assessed using approxi-
mate F tests and between each pair of groups using approxi-
mate t tests on the estimated marginal means. Finally,
concentrations of GAP-43 in healthy controls were com-
pared to those of stroke patients at each time group using
Mann-Whitney U tests, with correction for multiple com-
parisons using Holm’s procedure.
All tests were two-sided with a significance level set to
p = 0.05. All statistical analysis was performed using the
R programming language (version 3.4.3) with the nlme
(version 3.1) and emmeans (version 1.2) packages being
used for mixed effects modelling specifically.
Results
Patient demographics
Demographics of study participants are provided in Table 1.
The control group was age matched to the clinical stroke
group although with a larger percentage of females. There
was no correlation between age and CSF GAP-43 concentra-
tion in stroke or control groups (rs (day 0–4) = 0.43, p= 0.13;
control: rs = − 0.23, p= 0.34) and no differences between gen-
der (stroke (day 0–4): p= 0.78; control: p= 0.45). For white
matter lesion status in the stroke patients, there were
nine individuals who scored as normal, eight as spor-
adic, four as moderate, and three as pronounced. For
brain atrophy, 15 individuals were scored as normal,
one as general-light, three as general-moderate, and
five as cortical-light.
Assay validation results
The average intra- and inter-assay variation was assessed by
determining the coefficient of variation (CV) of repeated
analysis. The intra- and inter-assay CVs were 3.4 and 7.4%
respectively, for a sample with a mean GAP-43 concentra-
tion of 1184 pg/ml, and 3.2 and 5.8% respectively, for a sam-
ple with a mean GAP-43 concentration of 3117 pg/ml. The
LLOQ was 315 pg/ml and ULOQ was 10,000 pg/ml. The
parallelism was 85–100% for samples diluted 2–8 times. Re-
covery was 99–109%. No neurogranin interference was de-
tected (spike sample (1751 pg/ml); GAP-43 recovery was
101% of neat sample (1734 pg/ml)). All stability aliquots were
analyzed simultaneously and their concentrations differed
between 81 and 116% for samples with different storage con-
ditions, and 75–115% for freeze-thaw cycled aliquots, com-
pared to the original sample stored at − 80 °C.
CSF GAP-43 concentration increases directly after stroke
and eventually returns to initial levels
CSF GAP-43 concentrations in controls and change over
time in stroke patients are depicted in Fig. 1. GAP-43 con-
centration increased significantly over time relative to base-
line in the first 9 days after stroke (relative change: + 19%
per day, 95% CI [11.1, 26.9]; F1,32 = 24.8, P < 0.0001, Fig. 1a).
This result also held when viewing GAP-43 in absolute terms
(absolute change: + 506.6 pg/mL per day, 95% CI [204.0,
809.3], F1,32 = 11.7, P= 0.002, Fig. 1b). Additionally, GAP-43
concentrations between Days 7–9 were significantly ele-
vated compared to Days 0–1 (relative difference: 86.4, 95%
CI [11.8, 161.0]; t31 = 2.4, P = 0.02, Fig. 1a) and compared
to Days 2–3 (relative difference: 74.5, 95% CI [15.8, 133.4];
t31 = 2.6, P = 0.02, Fig. 1a).
Additionally, GAP-43 concentration decreased significantly
starting 9 days after stroke relative to baseline (relative
change: − 0.6% per day, 95% CI [0.3, 1.2]; F1,38 = 4.5, P= 0.04)
and absolute GAP-43 concentrations also decreased signifi-
cantly over the same period (absolute change: − 30.2 pg/mL
per day, 95% CI [− 5.7, − 54.7]; F1,38 = 6.2, P= 0.02). Add-
itionally, GAP-43 concentrations between 3 and 5
months were significantly lower compared to 3 weeks
(relative difference: 86.1, 95% CI [2.1, 170.2]; t40 = 2.6,
P = 0.04) and compared to Days 7–9 (relative differ-
ence: 81.3, 95% CI [− 4.2, 166.8]; t40 = 2.4, P = 0.04).
Overall, GAP-43 concentration increased slightly relative
to baseline (mean: 100%) in Days 2–3 (mean: 118.1%) and
increased greatly in Days 7–9 (mean: 187.1%), then began to
decrease relative to Days 7–9 after 3 weeks (mean: 166.6%)
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and returned to initial levels after 3–5months (mean:
89.8%). Continuous individual longitudinal trajectories of
absolute GAP-43 concentration after stroke are shown in
Fig. 1b, where each line represents a single individual (right
of dotted line), showing that most stroke suffering individ-
uals returned to control levels (Fig. 1b). The initial increase
in GAP-43 concentration before 9 days was highly corre-
lated with the subsequent decrease in GAP-43 levels over
time (r = − 0.65, P = 0.0005; see Fig. 1c), indicating that the
individuals with the largest initial increases in GAP-43 were
more likely to have larger subsequent decreases in GAP-43
concentration later on.
Compared to cross-sectional measurements of healthy con-
trols, absolute GAP-43 concentration in stroke patients was
significantly elevated in Days 7–9 (median difference: 1628 pg/
mL, 95% CI [333, 3905]; P= 0.007, Fig. 1d) and 3 weeks
after stroke (median difference: 1115 pg/mL, 95% CI
[106, 2467]; P = 0.02, Fig. 1d), but not in Days 0–1
(median difference: − 207 pg/mL, 95% CI [− 1252,
537]; P = 0.58, Fig. 1d), Days 2–3 (median difference:
270 pg/mL, 95% CI [− 390, 1388]; P = 0.44, Fig. 1d),
or 3–5 months (median difference: − 128 pg/mL, 95%
CI [− 774, 567]; P = 0.73, Fig. 1d) after stroke.
Association between GAP-43 change and stroke severity,
white matter lesions, brain atrophy and infarct size
In the first 9 days after stroke, the increase in GAP-43 concen-
tration was significantly associated with change in stroke se-
verity as measured by the modified SSI scale (r= 0.49, P=
0.01, Fig. 2a). This association was strengthened when consid-
ering only those patients whose SSI scores improved over time
(r= 0.82, P=0.002). However, there was no correlation be-
tween the change in GAP-43 concentration over time and the
change of stroke severity (r=− 0.05, P= 0.84, Fig. 2b) in the
time period after 9 days.
The change in GAP-43 concentration until 9 days after
stroke significantly differed overall across white matter
lesion status (F3,27 = 4.1, P = 0.017), but not for change in
GAP-43 concentration later on (F3,33 = 0.61, P = 0.61).
However, there was no significant difference between
GAP-43 changes for any two specific white matter lesion
groups likely due to lack of statistical power (see Add-
itional file 1 for F and P-values).
Additionally, the change in GAP-43 concentrations up to 9
days after stroke again significantly differed across brain atro-
phy status (F3,26 = 6.1, P= 0.003), but not for GAP-43 concen-
trations after 9 days (F3,31 = 0.14, P= 0.93). Again, there was
no significant difference between GAP-43 changes for any
two specific brain atrophy groups likely due to lack of statis-
tical power (see Additional file 1 for F and P-values).
The initial increase in GAP-43 concentration over the
first 9 days correlated positively with infarct size (r = 0.75,
P < 0.0001), indicating that those with higher infarct size
also had larger initial increase in GAP-43 levels. Meanwhile,
the later decrease in GAP-43 concentration after 9 days
correlated negatively with infarct size (r = − 0.64, P = 0.001).
Discussion
In this study, we detected a transient increase in CSF GAP-43
concentration after acute ischemic stroke that was most
prominent during the first 2 weeks after injury. As CSF is in
direct contact with the brain, its content can reflect ongoing
processes in the brain tissue. Animal models of ischemia sug-
gest that the content of GAP-43 in the brain may be the result
of both an increase due to regeneration responses and a de-
crease due to disrupted axons at the site of injury [11, 17, 18].
The temporary increase in CSF GAP-43 in our study likely re-
flects an increase due to regenerative responses, however addi-
tive effects of leakage of this synaptic protein from damaged
neurons cannot be ruled out. Substantial axonal sprouting
Table 1 Study participant demographics, clinical and biochemical data
Controls Stroke patients
Demographics
No. 19 28
Age 66 (±7) 64 (±11)
Gender (% male) 47% 75%
SSI 0 < 15 < 30 (n) 23/ 5/ 0
White matter lesion: normal/sporadic/moderate/ pronounced (n) 9/ 8/ 4/ 3
Atrophy: normal/ general sporadic/general moderate/cortical sporadic (n) 15/ 1/ 3/ 5
GAP-43 (pg/ml) 2711 (2021–3602)
Day 0–1 (n = 8) 2008 (1762–2954)
Day2–4 (n = 23) 3311 (2057–5491)
Day7–9 (n = 26) 3819 (2531–7242)
3 weeks (n = 22) 3949 (2668–6606)
3–5 months (n = 24) 2562 (2112–2821)
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and cortical reorganization is initiated after stroke and re-
ported in patients and experimental stroke models [22–26].
The CSF GAP-43 concentration in control subjects was
similar to most stroke patients at admission (Day 0–1, Day 2–
3) and the following increase during the first 9 days after
stroke indicate that increased CSF GAP-43 results from a de-
layed or progressing process. Different mechanisms of
ischemia-induced cell death are acutely activated in the ische-
mic core, appearing within a time-window of 0–2 days [27]. In
addition, delayed neuronal death is known to appear several
days after ischemia and progressing weeks after the injury [28,
29]. The delayed increase of GAP-43 in CSF may reflect the
time it takes for neuronal injury to spread across larger
peri-infarct areas, or reflect the time it takes for GAP-43 ex-
pressing neurons to die, with release of GAP-43 to the extra-
cellular space and CSF. This is further supported by a study
reporting decreased numbers of GAP-43 expressing cortical
cells in post-ischemic patients [30]. Also, GAP-43 expressing
neurons may be more resistant to the direct ischemic event. It
has been suggested that different types of neurons are differ-
ently susceptible to early and delayed cell death after ischemic
injuries [31].
Fig. 1 Transient increase in CSF GAP-43 concentration after stroke. a GAP-43 concentration relative to each individual’s baseline and a piecewise-linear
regression model displaying overall longitudinal trends between the five time points; b Baseline GAP-43 levels in controls (left of dotted line) and
continuous individual longitudinal trajectories of absolute GAP-43 concentration after stroke, where each line represents a single individual (right of
dotted line), showed a transient increase directly after stroke which returned to control levels for most individuals; c Relationship between the increase
in GAP-43 concentration before 9 days and the subsequent decrease in GAP-43 concentration after 9 days; d GAP-43 concentration (median and
interquartile range) in controls (left of dotted line) and in stroke patients at Day 0–1, Day 2–3, Day 7–9, 3 weeks and 3–5months
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Moreover, our results suggest an association of CSF
GAP-43 concentration and clinical characteristics during the
first 2 weeks after ischemia. Larger increase in CSF GAP-43
was related not necessarily to a worsening in clinical charac-
teristics but rather a lack of improvement, given that all but
one individual either improved or stayed the same over the
course of the study. This connection was even stronger when
analyzing only those patients whose clinical characteristics
actually improved. The connection to white matter lesions
indicates that GAP-43 levels were likely to increase more in
individuals with pronounced white matter lesions. Similarly,
a high increase in CSF GAP-43 concentration was related to
more severe atrophy and larger infarct size. Together with
weaker, or the lack of, association with clinical measures at
later time points, this suggests that CSF GAP-43 concentra-
tion primarily reflect the degree of, or response to, neuronal
injury but not recovery. Limitations of this study include the
relatively low sample number and the rather long sample
storage time. The reason for the long sample storage time is
that a stable CSF GAP-43 quantification method was just re-
cently developed and this evaluation of CSF GAP-43 in lon-
gitudinal stroke samples was possible through a previous
established collaboration. However, longitudinal studies have
the advantage of letting each patient be its own control at
baseline and individual changes over time should not be con-
siderably affected assuming equal effects of storage on all
samples. An additional limitation is the use of the
modified version of the SSI, which is not standard-
ized internationally. Nonetheless, we show for the
first time that changes in CSF GAP-43 after stroke
are connected to clinical measures. Additional stud-
ies are required to further evaluate the value of
GAP-43 as a stroke biomarker and elucidate its con-
nections to injury progression and clinical outcome.
CSF GAP-43 could become useful as a quantitative
measure of the regenerative response during
recovery, which should simplify comparison and
evaluation of both stroke treatments and rehabilita-
tion strategies.
Importantly, the results reported here, demonstrat-
ing a clear effect of ischemia on CSF GAP-43 con-
centrations, need to be considered when using CSF
GAP-43 as a biomarker in other settings. In a previ-
ous study of several dementia disorders, we have
shown a specific increase in CSF GAP-43 in Alzhei-
mer’s disease compared to several other neurodegen-
erative diseases [21]. As increased CSF GAP-43
concentration was associated to Alzheimer’s disease
neuropathology and correlated with cognitive de-
cline, it could be useful as an outcome marker in
clinical trials for novel Alzheimer’s disease therapeu-
tics. As stroke is likely to occur in a fraction of the
study population during a drug trial period, it would
be important to take into consideration that CSF
GAP-43 is transiently increased after stroke affecting
outcome levels. Other CSF biomarkers such as t-tau,
p-tau and neurogranin have also been evaluated in
stroke as well as traumatic brain injury to elucidate
mechanisms of neuronal injury reflected by particu-
lar biomarkers [32–36]. It was found that t-tau, but
not p-tau, increased after stroke suggesting they re-
flect different disease/injury mechanisms [33, 36].
Similar to our findings, CSF t-tau and neurogranin
concentrations were related to stroke characteristics
[32, 34]. Although CSF GAP-43 was previously found
largely selective for Alzheimer’s disease among neurodegener-
ative diseases, it may be altered by yet other conditions besides
stroke. Changes of GAP-43 expression levels in experimental
models of epilepsy and traumatic brain injury urges for add-
itional investigations of CSF GAP-43 change in epilepsy and
traumatic brain injury patients to find out the potential use of
GAP-43 concentration as a neuronal injury biomarker.
Fig. 2 Association of CSF GAP-43 to clinical characteristics. a Relationship between increase in GAP-43 concentration and the worsening of
clinical stroke severity score in the period until 9 days after stroke; b the same as panel a, but for the period after 9 days after stroke
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Conclusion
The transient increase of CSF GAP-43 appearing most in-
tensely at 1–3weeks after stroke is important to take into ac-
count when used as a biomarker for other neurodegenerative
diseases. Our findings also suggest that CSF GAP-43 may be a
marker of neuronal injury responses in stroke and urge for
additional studies confirming the potential of CSF GAP-43 to
reflect severity and outcome of stroke in larger cohorts.
Additional file
Additional file 1: Table of t and p values across the different white
matter lesion status and brain atrophy status groups, up to 9 days and,
after 9 days past the stroke. (XLSX 9 kb)
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